24 Results Found

4 historical designations highlight groundbreaking scientific achievements

Scientific achievements can significantly alter the course of history — for individuals, families and communities as well as for future scientific developments. We’re proud to have been recognized for our own contributions to science by the American Chemical Society (ACS), which has granted Merck four National Historic Chemical Landmarks (NHCL) designations since 1999. This ACS […]

search result image

35 Years: The Mectizan® Donation Program

For centuries, river blindness — also known as onchocerciasis — plagued remote communities in Africa, Latin America and Yemen, and there was no answer to this affliction. This all began to change in the mid-to-late 1970s when Dr. William Campbell of Merck Research Laboratories suggested the use of ivermectin (later named Mectizan) for river blindness […]

search result image

Merck Statement on Ivermectin use During the COVID-19 Pandemic

KENILWORTH, N.J., Feb. 4, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic. Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy […]

Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts

Grants Will Be Administered through the MECTIZAN® Donation Program and Will Support Precautionary Measures Required to Prevent the Spread of SARS-CoV-2 During Mass Drug Administration Programs for These Two Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN® Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF). The funds are being provided by Merck and will be administered through an application process managed by the MDP, a public-private partnership that oversees elimination efforts of these two diseases. This funding will be offered in the form of grants to support the implementation of the World Health Organization’s (WHO’s) recommended precautionary measures to decrease the risk of the spread of SARS-CoV-2 during mass drug administration (MDA). This press release features multimedia.

SUPRAMEC® (ivermectin) Pour-On

For more information, please visit our safety data sheets (SDS) page.

IVOTAN® (ivermectin) Subcutaneous Injection

For more information, please visit our safety data sheets (SDS) page.

RANGER® (ivermectin with propylene glycol) Injection

For more information, please visit our safety data sheets (SDS) page.

MECTIZAN®(ivermectin) Tablet for Oral Use

For more information, please visit our safety data sheets (SDS) page.

RANGER® LA 3.5% (ivermectin) Injection

For more information, please visit our safety data sheets (SDS) page.

1-10 of 24